|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
EP3067047B1
(en)
|
2005-12-08 |
2022-04-20 |
Insmed Incorporated |
Lipid-based compositions of antiinfectives for treating pulmonary infections
|
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
|
EP2679224A1
(en)
|
2007-08-01 |
2014-01-01 |
University of Pittsburgh of the Commonwealth System of Higher Education |
Nitro oleic acid modulation of type II diabetes
|
|
AU2008342535B2
(en)
|
2007-12-27 |
2015-02-05 |
Arbutus Biopharma Corporation |
Silencing of polo-like kinase expression using interfering RNA
|
|
JP5475753B2
(ja)
|
2008-04-15 |
2014-04-16 |
プロチバ バイオセラピューティクス インコーポレイティッド |
核酸送達用の脂質製剤
|
|
DK2280928T3
(en)
|
2008-05-01 |
2018-11-05 |
Complexa Inc |
Vinyl-substituted fatty acids
|
|
US20140024713A1
(en)
|
2008-06-19 |
2014-01-23 |
University Of Utah Research Foundation |
Use of nitrated lipids for treatment of side effects of toxic medical therapies
|
|
WO2009155439A2
(en)
|
2008-06-19 |
2009-12-23 |
University Of Utah Research Foundation |
Use of nitrated lipids for treatment of side effects of toxic medical therapies
|
|
EP3225621A1
(en)
*
|
2008-10-09 |
2017-10-04 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
AU2015249072C1
(en)
*
|
2008-10-20 |
2022-10-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
|
JP5791505B2
(ja)
*
|
2008-10-20 |
2015-10-07 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
トランスチレチンの発現を阻害するための組成物および方法
|
|
CN104910025B
(zh)
|
2008-11-07 |
2019-07-16 |
麻省理工学院 |
氨基醇类脂质和其用途
|
|
US8722082B2
(en)
|
2008-11-10 |
2014-05-13 |
Tekmira Pharmaceuticals Corporation |
Lipids and compositions for the delivery of therapeutics
|
|
MX338780B
(es)
|
2008-11-10 |
2016-05-02 |
Alnylam Pharmaceuticals Inc |
Lipidos y composiciones novedosas para el suministro de terapeuticos.
|
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
|
EP3243504A1
(en)
*
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Improved lipid formulation
|
|
CA2754043A1
(en)
*
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
|
CA2760706C
(en)
*
|
2009-05-05 |
2019-08-06 |
Alnylam Pharmaceuticals, Inc. |
Methods of delivering oligonucleotides to immune cells
|
|
PL2440183T3
(pl)
|
2009-06-10 |
2019-01-31 |
Arbutus Biopharma Corporation |
Ulepszona formulacja lipidowa
|
|
NZ597504A
(en)
*
|
2009-06-15 |
2013-10-25 |
Alnylam Pharmaceuticals Inc |
Lipid formulated dsrna targeting the pcsk9 gene
|
|
US9051567B2
(en)
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
|
EP2449106B1
(en)
|
2009-07-01 |
2015-04-08 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
CA2767127A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
|
EP2459189A4
(en)
|
2009-07-31 |
2013-01-16 |
Univ Pittsburgh |
FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS
|
|
EP3072881A1
(en)
|
2009-08-20 |
2016-09-28 |
Sirna Therapeutics, Inc. |
Novel cationic lipids with various head groups for oligonucleotide delivery
|
|
WO2011038160A2
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
CA2781276A1
(en)
|
2009-10-02 |
2011-04-07 |
Complexa, Inc. |
Heteroatom containing substituted fatty acids
|
|
US9101643B2
(en)
|
2009-11-03 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
|
|
EP3318248B1
(en)
|
2009-12-01 |
2019-04-10 |
Translate Bio, Inc. |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
|
WO2011088309A1
(en)
|
2010-01-14 |
2011-07-21 |
Regulus Therapeutics Inc. |
Microrna compositions and methods
|
|
EP2526113B1
(en)
|
2010-01-22 |
2016-08-10 |
Sirna Therapeutics, Inc. |
Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
|
|
EP2558074B1
(en)
|
2010-04-08 |
2018-06-06 |
The Trustees of Princeton University |
Preparation of lipid nanoparticles
|
|
EP2567952A4
(en)
*
|
2010-04-28 |
2015-11-25 |
Kyowa Hakko Kirin Co Ltd |
CATIONIC LIPID
|
|
US9408914B2
(en)
|
2010-04-28 |
2016-08-09 |
Kyowa Hakko Kirin Co., Ltd. |
Cationic lipid
|
|
WO2011141704A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc |
Novel cyclic cationic lipids and methods of use
|
|
EP2569276B1
(en)
*
|
2010-05-12 |
2021-02-24 |
Arbutus Biopharma Corporation |
Novel cationic lipids and methods of use thereof
|
|
WO2011141703A1
(en)
*
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics Inc. |
Compositions and methods for silencing apolipoprotein b
|
|
JP2013531634A
(ja)
|
2010-05-24 |
2013-08-08 |
メルク・シャープ・エンド・ドーム・コーポレイション |
オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
|
|
EP4481047A3
(en)
|
2010-06-03 |
2025-04-16 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
|
US11291635B2
(en)
|
2010-07-06 |
2022-04-05 |
Glaxosmithkline Biological Sa |
Virion-like delivery particles for self-replicating RNA molecules
|
|
CA2804396C
(en)
|
2010-07-06 |
2021-06-29 |
Novartis Ag |
Liposomes with lipids having an advantageous pka-value for rna delivery
|
|
HRP20160805T1
(hr)
|
2010-07-06 |
2016-08-12 |
Glaxosmithkline Biologicals Sa |
Imuniziranje velikih sisavaca malim dozama rna
|
|
LT3243526T
(lt)
|
2010-07-06 |
2020-02-10 |
Glaxosmithkline Biologicals S.A. |
Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
|
|
WO2012016184A2
(en)
*
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
HUE044815T2
(hu)
|
2010-08-17 |
2019-11-28 |
Sirna Therapeutics Inc |
Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
|
|
WO2012027467A1
(en)
|
2010-08-26 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
WO2012027675A2
(en)
|
2010-08-26 |
2012-03-01 |
Massachusetts Institute Of Technology |
Poly(beta-amino alcohols), their preparation, and uses thereof
|
|
WO2012030683A2
(en)
|
2010-08-31 |
2012-03-08 |
Merck Sharp & Dohme Corp. |
Novel single chemical entities and methods for delivery of oligonucleotides
|
|
SI3981427T1
(sl)
|
2010-08-31 |
2022-08-31 |
Glaxosmithkline Biologicals S.A. |
Pegilirani liposomi za dostavo imunogen-kodirajoče RNA
|
|
US9549901B2
(en)
|
2010-09-03 |
2017-01-24 |
The Brigham And Women's Hospital, Inc. |
Lipid-polymer hybrid particles
|
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
|
ES2888231T3
(es)
|
2010-09-20 |
2022-01-03 |
Sirna Therapeutics Inc |
Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
|
|
EP2621480B1
(en)
|
2010-09-30 |
2018-08-15 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
ES3005233T3
(en)
|
2010-10-01 |
2025-03-14 |
Modernatx Inc |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
|
CN103269713B
(zh)
|
2010-10-11 |
2016-01-20 |
诺华有限公司 |
抗原递送平台
|
|
EP3485913A1
(en)
|
2010-10-21 |
2019-05-22 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
|
EP2635265B1
(en)
|
2010-11-05 |
2018-04-04 |
Sirna Therapeutics, Inc. |
Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
|
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
|
CA2831392C
(en)
|
2011-03-28 |
2020-04-28 |
Massachusetts Institute Of Technology |
Conjugated lipomers and uses thereof
|
|
DE12722942T1
(de)
|
2011-03-31 |
2021-09-30 |
Modernatx, Inc. |
Freisetzung und formulierung von manipulierten nukleinsäuren
|
|
CA3198966A1
(en)
|
2011-06-08 |
2012-12-13 |
Translate Bio, Inc. |
Cleavable lipids
|
|
EP2717893B1
(en)
|
2011-06-08 |
2019-05-08 |
Translate Bio, Inc. |
Lipid nanoparticle compositions and methods for mrna delivery
|
|
EP3854413A1
(en)
|
2011-07-06 |
2021-07-28 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
|
BR112014000236A2
(pt)
|
2011-07-06 |
2017-02-14 |
Novartis Ag |
lipossomas com razão n:p útil para a liberação de moléculas de rna, composição e uso de ditos lipossomas
|
|
EP2744491B1
(en)
|
2011-08-19 |
2020-07-29 |
The University of Utah Research Foundation |
Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
|
|
US9126966B2
(en)
*
|
2011-08-31 |
2015-09-08 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use thereof
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
RU2648950C2
(ru)
|
2011-10-03 |
2018-04-02 |
Модерна Терапьютикс, Инк. |
Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
|
|
US9271952B2
(en)
*
|
2011-10-11 |
2016-03-01 |
Complexa, Inc. |
Compositions and methods for treating nephropathy
|
|
WO2013063468A1
(en)
|
2011-10-27 |
2013-05-02 |
Massachusetts Institute Of Technology |
Amino acid derivates functionalized on the n- terminal capable of forming drug incapsulating microspheres
|
|
IL284530B
(en)
*
|
2011-11-18 |
2022-07-01 |
Alnylam Pharmaceuticals Inc |
rnai factors, preparations and methods of using them for the treatment of transthyretin-related diseases
|
|
CA2856737C
(en)
*
|
2011-12-07 |
2023-09-26 |
Alnylam Pharmaceuticals, Inc. |
Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
|
|
EP2788006A1
(en)
|
2011-12-07 |
2014-10-15 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
|
WO2013086373A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Lipids for the delivery of active agents
|
|
AU2012352180A1
(en)
|
2011-12-16 |
2014-07-31 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
|
US20150306130A1
(en)
|
2012-01-27 |
2015-10-29 |
Hoffmann-La Roche Inc. |
Chitosan covalently linked with small molecule integrin antagonist for targeted delivery
|
|
WO2013110578A1
(en)
|
2012-01-27 |
2013-08-01 |
F. Hoffmann-La Roche Ag |
Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3
|
|
EP2806897B1
(en)
|
2012-01-27 |
2017-08-02 |
F. Hoffmann-La Roche AG |
Integrin antagonist conjugates for targeted delivery to cells expressing lfa-1
|
|
KR20140127234A
(ko)
|
2012-01-27 |
2014-11-03 |
에프. 호프만-라 로슈 아게 |
Vla-4 발현 세포로의 표적화된 전달을 위한 인테그린 안타고니스트 접합체
|
|
AU2013222179B2
(en)
|
2012-02-24 |
2017-08-24 |
Arbutus Biopharma Corporat ion |
Trialkyl cationic lipids and methods of use thereof
|
|
CN102600173B
(zh)
*
|
2012-03-02 |
2013-05-29 |
海南美兰史克制药有限公司 |
氨氯地平/贝那普利药物组合物脂质体固体制剂
|
|
US10322089B2
(en)
*
|
2012-03-14 |
2019-06-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nanoparticles, nanoparticle delivery methods, and systems of delivery
|
|
WO2013143555A1
(en)
*
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
CA2868034C
(en)
|
2012-03-29 |
2021-07-27 |
Shire Human Genetic Therapies, Inc. |
Ionizable cationic lipids
|
|
HK1206644A1
(en)
|
2012-03-29 |
2016-01-15 |
Shire Human Genetic Therapies, Inc. |
Lipid-derived neutral nanoparticles
|
|
AU2013243949A1
(en)
*
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
CA2870941C
(en)
|
2012-04-19 |
2021-05-25 |
Sirna Therapeutics, Inc. |
Diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
|
WO2013185069A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Pulmonary delivery of mrna to non-lung target cells
|
|
WO2013185067A1
(en)
|
2012-06-08 |
2013-12-12 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
TW201408625A
(zh)
|
2012-07-06 |
2014-03-01 |
Kyowa Hakko Kirin Co Ltd |
陽離子性脂質
|
|
US9415109B2
(en)
|
2012-07-06 |
2016-08-16 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
|
CA2884870C
(en)
|
2012-08-13 |
2022-03-29 |
Massachusetts Institute Of Technology |
Amine-containing lipidoids and uses thereof
|
|
EP2885419A4
(en)
|
2012-08-14 |
2016-05-25 |
Moderna Therapeutics Inc |
ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
|
|
HRP20220607T1
(hr)
|
2012-11-26 |
2022-06-24 |
Modernatx, Inc. |
Terminalno modificirana rna
|
|
EP3581186A1
(en)
|
2012-11-29 |
2019-12-18 |
Insmed Incorporated |
Stabilized vancomycin formulations
|
|
ES2968649T3
(es)
|
2012-12-07 |
2024-05-13 |
Translate Bio Inc |
Nanopartículas lipídicas para la administración de ARNm en los pulmones
|
|
TR201901310T4
(tr)
|
2013-03-14 |
2019-02-21 |
Translate Bio Inc |
Mesajcı RNA'nın saflaştırılması yöntemleri.
|
|
LT2968586T
(lt)
|
2013-03-14 |
2018-11-26 |
Translate Bio, Inc. |
Cft mrnr kompozicijos bei su jomis susiję būdai ir panaudojimai
|
|
EP2971010B1
(en)
|
2013-03-14 |
2020-06-10 |
ModernaTX, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
JP6399560B2
(ja)
|
2013-03-14 |
2018-10-03 |
トランスレイト バイオ, インコーポレイテッド |
mRNAによってコードされる抗体を送達するための方法及び組成物
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
DK2972360T3
(en)
|
2013-03-15 |
2018-05-22 |
Translate Bio Inc |
SYNERGISTIC IMPROVEMENT OF DELIVERY OF NUCLEIC ACIDS THROUGH MIXED FORMULATIONS
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
US9315472B2
(en)
|
2013-05-01 |
2016-04-19 |
Massachusetts Institute Of Technology |
1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
|
|
TW201534578A
(zh)
|
2013-07-08 |
2015-09-16 |
Daiichi Sankyo Co Ltd |
新穎脂質
|
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
KR20160067219A
(ko)
|
2013-10-03 |
2016-06-13 |
모더나 세라퓨틱스, 인코포레이티드 |
저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
|
|
CN105658800A
(zh)
|
2013-10-22 |
2016-06-08 |
夏尔人类遗传性治疗公司 |
Mrna的cns递送及其用途
|
|
CN112618732A
(zh)
|
2013-10-22 |
2021-04-09 |
夏尔人类遗传性治疗公司 |
用于递送信使rna的脂质制剂
|
|
BR112016009014B1
(pt)
|
2013-10-22 |
2024-02-06 |
Translate Bio, Inc |
USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
|
|
EP3574923A1
(en)
|
2013-10-22 |
2019-12-04 |
Translate Bio, Inc. |
Mrna therapy for phenylketonuria
|
|
EP3985118A1
(en)
|
2013-11-22 |
2022-04-20 |
MiNA Therapeutics Limited |
C/ebp alpha short activating rna compositions and methods of use
|
|
AU2014383024B2
(en)
|
2013-12-03 |
2020-04-30 |
Exicure, Inc. |
Liposomal particles, methods of making same and uses thereof
|
|
WO2015105131A1
(ja)
*
|
2014-01-09 |
2015-07-16 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
カチオン性脂質
|
|
WO2015130584A2
(en)
|
2014-02-25 |
2015-09-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
|
EP3122878B1
(en)
|
2014-03-24 |
2018-10-24 |
Translate Bio, Inc. |
Mrna therapy for the treatment of ocular diseases
|
|
ES3009962T3
(en)
|
2014-04-23 |
2025-03-31 |
Modernatx Inc |
Nucleic acid vaccines
|
|
KR102739894B1
(ko)
|
2014-04-25 |
2024-12-05 |
샤이어 휴먼 지네틱 테라피즈 인크. |
메신저 rna 의 정제 방법
|
|
KR20240018675A
(ko)
|
2014-05-15 |
2024-02-13 |
인스메드 인코포레이티드 |
폐의 비-결핵성 마이코박테리아 감염을 치료하기 위한 방법
|
|
CN105085292B
(zh)
*
|
2014-05-23 |
2017-12-15 |
上海交通大学 |
3‑((2‑(二甲氨基)乙烷基)(甲基)氨基)丙酸的两亲性衍生物及其用途
|
|
CN105085295A
(zh)
*
|
2014-05-23 |
2015-11-25 |
上海交通大学 |
氨甲环酸的两亲性衍生物及其用途
|
|
US10022455B2
(en)
|
2014-05-30 |
2018-07-17 |
Translate Bio, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
|
AU2015269412B2
(en)
|
2014-06-04 |
2020-03-12 |
Exicure Operating Company |
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
|
CN111588695A
(zh)
|
2014-06-24 |
2020-08-28 |
川斯勒佰尔公司 |
用于递送核酸的立体化学富集组合物
|
|
CN106795096B
(zh)
|
2014-06-25 |
2020-05-29 |
爱康泰生治疗公司 |
用于递送核酸的新型脂质和脂质纳米颗粒制剂
|
|
JP6641272B2
(ja)
|
2014-06-30 |
2020-02-05 |
協和キリン株式会社 |
カチオン性脂質
|
|
BR112016030852A2
(pt)
|
2014-07-02 |
2018-01-16 |
Shire Human Genetic Therapies |
encapsulação de rna mensageiro
|
|
WO2016004202A1
(en)
|
2014-07-02 |
2016-01-07 |
Massachusetts Institute Of Technology |
Polyamine-fatty acid derived lipidoids and uses thereof
|
|
GB201414464D0
(en)
|
2014-08-14 |
2014-10-01 |
Technion Res & Dev Foundation |
Compositions and methods for therapeutics prescreening
|
|
EP3183007B1
(en)
|
2014-08-19 |
2020-06-17 |
Northwestern University |
Protein/oligonucleotide core-shell nanoparticle therapeutics
|
|
CN107106874B
(zh)
|
2014-08-29 |
2021-08-31 |
阿尔尼拉姆医药品有限公司 |
治疗甲状腺素运载蛋白(ttr)介导的淀粉样变性的方法
|
|
WO2016090262A1
(en)
|
2014-12-05 |
2016-06-09 |
Shire Human Genetic Therapies, Inc. |
Messenger rna therapy for treatment of articular disease
|
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
|
AU2016233135B2
(en)
|
2015-03-19 |
2021-07-08 |
Translate Bio, Inc. |
mRNA therapy for pompe disease
|
|
AU2016237148A1
(en)
|
2015-03-24 |
2017-11-23 |
Kyowa Hakko Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticles
|
|
WO2016165831A1
(en)
|
2015-04-17 |
2016-10-20 |
Curevac Ag |
Lyophilization of rna
|
|
EP3289083A4
(en)
|
2015-04-27 |
2018-12-19 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
|
HK1251010A1
(zh)
|
2015-05-06 |
2019-01-18 |
Benitec IP Holdings Inc. |
用於治疗乙型肝炎病毒(hbv)感染的试剂及用途
|
|
CN104803863B
(zh)
*
|
2015-05-08 |
2016-07-20 |
厦门成坤生物技术有限公司 |
阳离子类脂化合物及其制备方法
|
|
EP3928800A3
(en)
|
2015-05-20 |
2022-03-23 |
CureVac AG |
Dry powder composition comprising long-chain rna
|
|
CN107635587A
(zh)
|
2015-05-20 |
2018-01-26 |
库瑞瓦格股份公司 |
包含长链rna的干燥粉末组合物
|
|
RS64331B1
(sr)
|
2015-06-19 |
2023-08-31 |
Massachusetts Inst Technology |
Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
|
|
HRP20240865T1
(hr)
|
2015-06-29 |
2024-10-11 |
Acuitas Therapeutics Inc. |
Lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
|
|
CN107810187B
(zh)
|
2015-07-07 |
2020-09-15 |
H.隆德贝克有限公司 |
用于治疗外周疾病的具有咪唑并三嗪酮骨架和咪唑并吡嗪酮骨架的pde9抑制剂
|
|
AU2016291228B2
(en)
*
|
2015-07-09 |
2020-04-09 |
Insmed Incorporated |
Compositions and methods for treating lung diseases and lung injury
|
|
MA42502A
(fr)
|
2015-07-21 |
2018-05-30 |
Modernatx Inc |
Vaccins contre une maladie infectieuse
|
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
|
JP6896703B2
(ja)
|
2015-07-31 |
2021-06-30 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
TTR関連疾患を治療または予防するためのトランスサイレチン(TTR)iRNA組成物およびその使用方法
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
WO2017035278A1
(en)
|
2015-08-24 |
2017-03-02 |
Halo-Bio Rnai Therapeutics, Inc. |
Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
|
|
ES2910425T3
(es)
|
2015-09-17 |
2022-05-12 |
Modernatx Inc |
Compuestos y composiciones para la administración intracelular de agentes terapéuticos
|
|
US10537541B2
(en)
|
2015-10-02 |
2020-01-21 |
Complexa Inc. |
Treatment of focal segmental glomerular sclerosis (FSGS) using therapeutically effective oral doses of 10-nitro-9(E)-octadec-9-enoic acid
|
|
US10849920B2
(en)
|
2015-10-05 |
2020-12-01 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017066497A2
(en)
|
2015-10-13 |
2017-04-20 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
CA3001852A1
(en)
|
2015-10-14 |
2017-04-20 |
Translate Bio, Inc. |
Modification of rna-related enzymes for enhanced production
|
|
US20180289792A1
(en)
|
2015-10-22 |
2018-10-11 |
ModernaTX. Inc. |
Sexually transmitted disease vaccines
|
|
CA3002922A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
PE20181529A1
(es)
|
2015-10-22 |
2018-09-26 |
Modernatx Inc |
Vacunas de acido nucleico para el virus varicela-zoster (vzv)
|
|
MD3718565T2
(ro)
|
2015-10-22 |
2022-09-30 |
Modernatx Inc |
Vaccinuri împotriva virusului respirator
|
|
WO2017070624A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Tropical disease vaccines
|
|
AU2016343803B2
(en)
|
2015-10-28 |
2021-04-29 |
Acuitas Therapeutics, Inc. |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
EP4644567A2
(en)
|
2015-11-30 |
2025-11-05 |
Duke University |
Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
|
|
AU2016366978B2
(en)
|
2015-12-10 |
2022-07-28 |
Modernatx, Inc. |
Compositions and methods for delivery of therapeutic agents
|
|
CN106883158B
(zh)
*
|
2015-12-15 |
2019-08-23 |
中国科学院广州生物医药与健康研究院 |
生物可降解的氨基脂质类化合物及其制备方法和应用
|
|
SMT202200252T1
(it)
|
2015-12-22 |
2022-07-21 |
Modernatx Inc |
Composti e composizioni per il rilascio intracellulare di agenti
|
|
US10525138B2
(en)
|
2015-12-25 |
2020-01-07 |
Kyowa Hakko Kirin Co., Ltd. |
Compound as cationic lipid
|
|
CN105622473B
(zh)
*
|
2016-02-06 |
2017-07-25 |
吴国球 |
一种阳离子氨基脂质及其合成方法和用途
|
|
US20190046638A1
(en)
|
2016-04-01 |
2019-02-14 |
Checkmate Pharmaceuticals, Inc. |
Fc RECEPTOR-MEDIATED DRUG DELIVERY
|
|
WO2017177169A1
(en)
|
2016-04-08 |
2017-10-12 |
Rana Therapeutics, Inc. |
Multimeric coding nucleic acid and uses thereof
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
EP3443091A4
(en)
|
2016-04-14 |
2019-11-27 |
Benitec Biopharma Limited |
REAGENTS FOR THE TREATMENT OF OCULOPHARYNGEAL MUSCLE DYSTROPHY (OPMD) AND USE THEREOF
|
|
AU2017261360A1
(en)
|
2016-05-06 |
2018-11-29 |
Exicure Operating Company |
Liposomal Spherical Nucleic Acid (SNA) constructs presenting Antisense Oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor MRNA
|
|
CA3024129A1
(en)
*
|
2016-05-16 |
2017-11-23 |
The Board Of Regents Of The University Of Texas System |
Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
|
|
EP3458074B1
(en)
*
|
2016-05-16 |
2024-04-17 |
Board of Regents of the University of Texas System |
COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH
|
|
US12128113B2
(en)
|
2016-05-18 |
2024-10-29 |
Modernatx, Inc. |
Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
|
|
KR102533456B1
(ko)
|
2016-05-18 |
2023-05-17 |
모더나티엑스, 인크. |
릴랙신을 인코딩하는 폴리뉴클레오타이드
|
|
EP3842530A1
(en)
|
2016-06-13 |
2021-06-30 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency
|
|
MX385488B
(es)
|
2016-06-24 |
2025-03-18 |
Eisai R&D Man Co Ltd |
Lipido cationico.
|
|
MX2018016389A
(es)
*
|
2016-06-30 |
2019-08-16 |
Arbutus Biopharma Corp |
Composiciones y metodos para suministro de arn mensajero.
|
|
WO2018017754A1
(en)
|
2016-07-19 |
2018-01-25 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
US20190185859A1
(en)
|
2016-08-19 |
2019-06-20 |
Curevac Ag |
Rna for cancer therapy
|
|
US11471533B2
(en)
|
2016-09-27 |
2022-10-18 |
Kyowa Kirin Co., Ltd. |
Compound usable as cationic lipid
|
|
WO2018062413A1
(ja)
*
|
2016-09-28 |
2018-04-05 |
協和発酵キリン株式会社 |
核酸含有脂質ナノ粒子
|
|
EP3528821A4
(en)
|
2016-10-21 |
2020-07-01 |
ModernaTX, Inc. |
HUMAN CYTOMEGALOVIRUS VACCINE
|
|
US20190314486A1
(en)
|
2016-10-21 |
2019-10-17 |
Merck Sharp & Dohme Corp. |
Influenza hemagglutinin protein vaccines
|
|
US12491261B2
(en)
|
2016-10-26 |
2025-12-09 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
EP3538136A1
(en)
|
2016-11-10 |
2019-09-18 |
Translate Bio, Inc. |
Subcutaneous delivery of messenger rna
|
|
AU2017357758B2
(en)
|
2016-11-10 |
2023-11-16 |
Translate Bio, Inc. |
Improved process of preparing mRNA-loaded lipid nanoparticles
|
|
CN110167587A
(zh)
|
2016-11-11 |
2019-08-23 |
摩登纳特斯有限公司 |
流感疫苗
|
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
|
US11103578B2
(en)
|
2016-12-08 |
2021-08-31 |
Modernatx, Inc. |
Respiratory virus nucleic acid vaccines
|
|
EP3551230A1
(en)
|
2016-12-08 |
2019-10-16 |
CureVac AG |
Rna for treatment or prophylaxis of a liver disease
|
|
EP3558354A1
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Lassa virus vaccine
|
|
EP3558355A2
(en)
|
2016-12-23 |
2019-10-30 |
CureVac AG |
Henipavirus vaccine
|
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
|
US11873496B2
(en)
|
2017-01-09 |
2024-01-16 |
Whitehead Institute For Biomedical Research |
Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops
|
|
BR112019014314A2
(pt)
|
2017-01-11 |
2020-02-18 |
The Trustees Of The University Of Pennsylvania |
Composição, e, método de indução de uma resposta imune adaptativa contra vírus zika.
|
|
WO2018151816A1
(en)
|
2017-02-16 |
2018-08-23 |
Modernatx, Inc. |
High potency immunogenic compositions
|
|
EP3585417B1
(en)
|
2017-02-27 |
2023-02-22 |
Translate Bio, Inc. |
Method of making a codon-optimized cftr mrna
|
|
EP3592728A1
(en)
|
2017-03-07 |
2020-01-15 |
Translate Bio, Inc. |
Polyanionic delivery of nucleic acids
|
|
MA47787A
(fr)
|
2017-03-15 |
2020-01-22 |
Modernatx Inc |
Vaccin contre le virus respiratoire syncytial
|
|
EP3609534A4
(en)
|
2017-03-15 |
2021-01-13 |
ModernaTX, Inc. |
WIDE SPECTRUM INFLUENZA VIRUS VACCINE
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
|
CA3055653A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
SI3596041T1
(sl)
|
2017-03-15 |
2023-02-28 |
Modernatx, Inc. |
Spojina in sestavki za intracelično dostavljanje terapevtskih sredstev
|
|
CA3056133A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
|
EP3595676A4
(en)
|
2017-03-17 |
2021-05-05 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZOONOSES
|
|
CA3050614A1
(en)
|
2017-03-17 |
2018-09-20 |
Curevac Ag |
Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
|
|
JP2020513824A
(ja)
|
2017-03-24 |
2020-05-21 |
キュアバック アーゲー |
Crispr関連タンパク質をコードする核酸、及びその使用
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
JP7464954B2
(ja)
|
2017-04-27 |
2024-04-10 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
C型肝炎ウイルスに対するヌクレオシド修飾mRNA-脂質ナノ粒子系統ワクチン
|
|
EP4410317A3
(en)
|
2017-04-28 |
2024-10-30 |
Acuitas Therapeutics Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
WO2018209270A1
(en)
|
2017-05-11 |
2018-11-15 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (snas)
|
|
CA3063531A1
(en)
|
2017-05-16 |
2018-11-22 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
|
JP7284101B2
(ja)
|
2017-05-31 |
2023-05-30 |
ウルトラジェニクス ファーマシューティカル インク. |
糖原病iii型のための治療薬
|
|
EP3630985B1
(en)
|
2017-05-31 |
2025-08-27 |
Arcturus Therapeutics, Inc. |
Synthesis and structure of high potency rna therapeutics
|
|
WO2018222925A1
(en)
|
2017-05-31 |
2018-12-06 |
Ultragenyx Pharmaceutical Inc. |
Therapeutics for phenylketonuria
|
|
EP3638678B1
(en)
|
2017-06-14 |
2025-12-03 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
EP3638215A4
(en)
|
2017-06-15 |
2021-03-24 |
Modernatx, Inc. |
RNA FORMULATIONS
|
|
EP3641834B1
(en)
|
2017-06-19 |
2023-10-04 |
Translate Bio, Inc. |
Messenger rna therapy for the treatment of friedreich's ataxia
|
|
EP4494652A3
(en)
|
2017-07-04 |
2025-05-14 |
CureVac SE |
Cancer rna-vaccine
|
|
US20210228738A1
(en)
|
2017-07-17 |
2021-07-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
|
|
CA3071968A1
(en)
|
2017-08-04 |
2019-02-07 |
Kyowa Kirin Co., Ltd. |
Nucleic acid-containing lipid nanoparticle
|
|
WO2019036008A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
|
EP3668834B1
(en)
|
2017-08-17 |
2024-10-02 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
|
EP4219715A3
(en)
|
2017-09-08 |
2023-09-06 |
MiNA Therapeutics Limited |
Stabilized cebpa sarna compositions and methods of use
|
|
US11447773B2
(en)
|
2017-09-08 |
2022-09-20 |
Mina Therapeutics Limited |
Stabilized HNF4A saRNA compositions and methods of use
|
|
US10653767B2
(en)
|
2017-09-14 |
2020-05-19 |
Modernatx, Inc. |
Zika virus MRNA vaccines
|
|
EP3684931A1
(en)
|
2017-09-19 |
2020-07-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
|
|
RU2020115287A
(ru)
|
2017-10-19 |
2021-11-19 |
Куревак Аг |
Новые молекулы искусственных нуклеиновых кислот
|
|
US11692002B2
(en)
|
2017-11-08 |
2023-07-04 |
CureVac SE |
RNA sequence adaptation
|
|
EP3723796A1
(en)
|
2017-12-13 |
2020-10-21 |
CureVac AG |
Flavivirus vaccine
|
|
MA51306A
(fr)
|
2017-12-20 |
2020-10-28 |
Translate Bio Inc |
Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
|
|
MX2020006843A
(es)
|
2017-12-27 |
2020-09-03 |
Takeda Pharmaceuticals Co |
Nanoparticula de lipido que contiene acido nucleico y uso de la misma.
|
|
CN111417621A
(zh)
|
2017-12-27 |
2020-07-14 |
卫材R&D管理有限公司 |
阳离子脂质
|
|
US11566051B2
(en)
|
2018-01-29 |
2023-01-31 |
Merck Sharp & Dohme Llc |
Stabilized RSV F proteins and uses thereof
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
EP3746496A1
(en)
|
2018-02-02 |
2020-12-09 |
Translate Bio, Inc. |
Cationic polymers
|
|
JP2021513508A
(ja)
*
|
2018-02-12 |
2021-05-27 |
インテアールエヌエー テクノロジーズ ビー.ヴイ.InteRNA Technologies B.V. |
抗がんマイクロrna及びその脂質製剤
|
|
WO2019160866A2
(en)
|
2018-02-13 |
2019-08-22 |
Checkmate Pharmaceuticals, Inc. |
Compositions and methods for tumor immunotherapy
|
|
WO2019191627A1
(en)
|
2018-03-30 |
2019-10-03 |
Insmed Incorporated |
Methods for continuous manufacture of liposomal drug products
|
|
WO2019193183A2
(en)
|
2018-04-05 |
2019-10-10 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
|
AU2019251421B2
(en)
|
2018-04-09 |
2025-05-01 |
Checkmate Pharmaceuticals |
Packaging oligonucleotides into virus-like particles
|
|
WO2019197845A1
(en)
|
2018-04-12 |
2019-10-17 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
EP4227319B1
(en)
|
2018-04-17 |
2025-11-26 |
CureVac SE |
Novel rsv rna molecules and compositions for vaccination
|
|
WO2019222277A1
(en)
|
2018-05-15 |
2019-11-21 |
Translate Bio, Inc. |
Subcutaneous delivery of messenger rna
|
|
CN112384523B
(zh)
|
2018-05-16 |
2025-03-14 |
川斯勒佰尔公司 |
核糖阳离子脂质
|
|
US12076439B2
(en)
|
2018-05-24 |
2024-09-03 |
Translate Bio, Inc. |
Thioester cationic lipids
|
|
CA3100988A1
(en)
|
2018-05-25 |
2019-11-28 |
Imara Inc. |
Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one
|
|
CN112424214A
(zh)
|
2018-05-30 |
2021-02-26 |
川斯勒佰尔公司 |
包含甾族部分的阳离子脂质
|
|
AU2019277361B2
(en)
|
2018-05-30 |
2025-04-24 |
Translate Bio, Inc. |
Messenger RNA vaccines and uses thereof
|
|
JP2021525743A
(ja)
|
2018-05-30 |
2021-09-27 |
トランスレイト バイオ, インコーポレイテッド |
リン酸エステルカチオン性脂質
|
|
MA52766A
(fr)
|
2018-05-30 |
2021-04-14 |
Translate Bio Inc |
Lipides cationiques vitaminiques
|
|
EP3813874A1
(en)
|
2018-06-27 |
2021-05-05 |
CureVac AG |
Novel lassa virus rna molecules and compositions for vaccination
|
|
EP3826608A1
(en)
|
2018-07-23 |
2021-06-02 |
Translate Bio, Inc. |
Dry power formulations for messenger rna
|
|
CA3108544A1
(en)
|
2018-08-24 |
2020-02-27 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
|
US11357726B2
(en)
|
2018-08-29 |
2022-06-14 |
Translate Bio, Inc. |
Process of preparing mRNA-loaded lipid nanoparticles
|
|
AU2019328299B2
(en)
|
2018-08-31 |
2025-02-20 |
Cardurion Pharmaceuticals, Inc. |
PDE9 inhibitors for treating sickle cell disease
|
|
EP3849617A1
(en)
|
2018-09-14 |
2021-07-21 |
Translate Bio, Inc. |
Composition and methods for treatment of methylmalonic acidemia
|
|
MA53650A
(fr)
|
2018-09-19 |
2021-07-28 |
Modernatx Inc |
Lipides peg et leurs utilisations
|
|
AU2019345067A1
(en)
|
2018-09-19 |
2021-04-08 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
|
US12263248B2
(en)
|
2018-09-19 |
2025-04-01 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
IL322436A
(en)
|
2018-09-21 |
2025-09-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
JP7387745B2
(ja)
|
2018-10-01 |
2023-11-28 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
活性物質の送達のための生分解性脂質
|
|
EP4379053A3
(en)
|
2018-10-09 |
2024-09-18 |
The University of British Columbia |
Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto
|
|
US20210381006A1
(en)
|
2018-10-18 |
2021-12-09 |
Takeda Pharmaceutical Company Limited |
Method for activation/proliferation of t cells
|
|
WO2020081933A1
(en)
|
2018-10-19 |
2020-04-23 |
Translate Bio, Inc. |
Pumpless encapsulation of messenger rna
|
|
BR112021008974A2
(pt)
|
2018-11-09 |
2021-08-03 |
Translate Bio, Inc. |
lipídios de 2,5-dioxopiperazina com frações éster, tioéster, dissulfeto e anidrido intercaladas
|
|
EP3876994A2
(en)
|
2018-11-09 |
2021-09-15 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
|
WO2020097376A1
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
Multi-peg lipid compounds
|
|
JP2022501064A
(ja)
|
2018-11-09 |
2022-01-06 |
アルブータス・バイオファーマー・コーポレイション |
ケイ素を含有するカチオン性脂質
|
|
EP3876914A2
(en)
|
2018-11-09 |
2021-09-15 |
Translate Bio, Inc. |
Messenger rna therapy for treatment of ocular diseases
|
|
US20220096612A1
(en)
|
2018-11-12 |
2022-03-31 |
Translatebioinc |
Methods for inducing immune tolerance
|
|
CA3120647A1
(en)
|
2018-11-21 |
2020-05-28 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
|
|
AU2019383413A1
(en)
|
2018-11-21 |
2021-05-27 |
Translate Bio, Inc. |
Cationic lipid compounds and compositions thereof for use in the delivery of messenger RNA
|
|
JP7445657B2
(ja)
|
2018-12-06 |
2024-03-07 |
アークトゥラス・セラピューティクス・インコーポレイテッド |
オルニチントランスカルバミラーゼ欠損症を処置するための組成物および方法
|
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
|
AU2019410737A1
(en)
|
2018-12-21 |
2021-06-10 |
CureVac SE |
RNA for malaria vaccines
|
|
AU2020206109B2
(en)
|
2019-01-07 |
2024-12-19 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
US11453639B2
(en)
|
2019-01-11 |
2022-09-27 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
CA3128215A1
(en)
*
|
2019-01-31 |
2020-08-06 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
|
CA3125511A1
(en)
|
2019-02-08 |
2020-08-13 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
EP3938379A4
(en)
|
2019-03-15 |
2023-02-22 |
ModernaTX, Inc. |
Hiv rna vaccines
|
|
CA3136265A1
(en)
|
2019-04-05 |
2020-10-08 |
Precision Biosciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
|
US20220211740A1
(en)
|
2019-04-12 |
2022-07-07 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
|
US20220177423A1
(en)
|
2019-04-18 |
2022-06-09 |
Translate Bio, Inc. |
Cystine cationic lipids
|
|
ES2972014T3
(es)
|
2019-04-22 |
2024-06-10 |
Translate Bio Inc |
Lípidos catiónicos de tioéster
|
|
WO2020227085A1
(en)
|
2019-05-03 |
2020-11-12 |
Translate Bio, Inc. |
Di-thioester cationic lipids
|
|
KR20220024022A
(ko)
|
2019-05-14 |
2022-03-03 |
트랜슬레이트 바이오 인코포레이티드 |
Mrna-로딩된 지질 나노입자를 제조하는 개선된 방법
|
|
CA3139032A1
(en)
|
2019-05-22 |
2020-11-26 |
Robert Alexander WESSELHOEFT |
Circular rna compositions and methods
|
|
US20220226244A1
(en)
|
2019-05-31 |
2022-07-21 |
Translate Bio, Inc. |
Macrocyclic lipids
|
|
EP3986452A1
(en)
|
2019-06-18 |
2022-04-27 |
CureVac AG |
Rotavirus mrna vaccine
|
|
WO2020257611A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Cationic lipids comprising an hydroxy moiety
|
|
JP7724161B2
(ja)
|
2019-06-21 |
2025-08-15 |
トランスレイト バイオ, インコーポレイテッド |
トリシンおよびクエン酸脂質
|
|
CN114450265B
(zh)
|
2019-07-03 |
2024-12-24 |
菲克特生物科学股份有限公司 |
阳离子脂质及其用途
|
|
KR20220078557A
(ko)
|
2019-07-08 |
2022-06-10 |
트랜슬레이트 바이오 인코포레이티드 |
개선된 mrna 로딩된 지질 나노입자 및 이의 제조 방법
|
|
EP3999642A1
(en)
|
2019-07-19 |
2022-05-25 |
Flagship Pioneering Innovations VI, LLC |
Recombinase compositions and methods of use
|
|
JP7630904B2
(ja)
*
|
2019-07-23 |
2025-02-18 |
株式会社東芝 |
核酸導入キャリア、核酸導入キャリアセット、核酸導入組成物及び核酸導入方法
|
|
US12144871B2
(en)
|
2019-07-23 |
2024-11-19 |
Translate Bio, Inc. |
Stable compositions of MRNA-loaded lipid nanoparticles and processes of making
|
|
US20220323542A1
(en)
|
2019-07-30 |
2022-10-13 |
Translate Bio, Inc. |
TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
|
|
US10501404B1
(en)
|
2019-07-30 |
2019-12-10 |
Factor Bioscience Inc. |
Cationic lipids and transfection methods
|
|
CA3144902A1
(en)
|
2019-08-14 |
2022-01-19 |
Andreas Thess |
Rna combinations and compositions with decreased immunostimulatory properties
|
|
CN120423969A
(zh)
|
2019-09-19 |
2025-08-05 |
摩登纳特斯有限公司 |
用于治疗剂的细胞内递送的支链尾端脂质化合物和组合物
|
|
MX2022003394A
(es)
|
2019-09-20 |
2022-06-22 |
Translate Bio Inc |
Arnm que codifica cftr manipulado.
|
|
AU2020355000A1
(en)
|
2019-09-23 |
2022-03-17 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein B (APOB) gene expression
|
|
JP2022548399A
(ja)
|
2019-09-23 |
2022-11-18 |
オメガ セラピューティクス, インコーポレイテッド |
肝細胞核因子4-アルファ(HNF4α)遺伝子発現をモジュレートするための組成物および方法
|
|
ES3028783T3
(en)
|
2019-10-09 |
2025-06-20 |
Translate Bio Inc |
Messenger rnas encoding sting and il-12 and use in the treatment of cancer
|
|
EP4045020A4
(en)
*
|
2019-10-18 |
2024-02-21 |
The Trustees of the University of Pennsylvania |
Lipid and lipid nanoparticle formulation for drug delivery
|
|
US20210145860A1
(en)
|
2019-10-21 |
2021-05-20 |
Translate Bio, Inc. |
Compositions, methods and uses of messenger rna
|
|
EP4289951A3
(en)
|
2019-12-04 |
2024-03-13 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
CA3162019A1
(en)
|
2019-12-20 |
2021-06-24 |
Gemma NAVARRO |
Lipid nanoparticles for delivery of nucleic acids
|
|
US12053551B2
(en)
|
2019-12-20 |
2024-08-06 |
Translate Bio, Inc. |
Process of preparing mRNA-loaded lipid nanoparticles
|
|
US20230051811A1
(en)
|
2019-12-20 |
2023-02-16 |
Translate Bio, Inc |
Rectal delivery of messenger rna
|
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
|
CA3160511A1
(en)
|
2020-02-04 |
2021-08-12 |
Susanne RAUCH |
Coronavirus vaccine
|
|
US11638754B2
(en)
|
2020-02-14 |
2023-05-02 |
Merck Sharp & Dohme Llc |
HPV vaccine
|
|
JP7744354B2
(ja)
|
2020-02-25 |
2025-09-25 |
トランスレイト バイオ, インコーポレイテッド |
Mrna担持脂質ナノ粒子を調製する改善された方法
|
|
JP2023516676A
(ja)
|
2020-03-03 |
2023-04-20 |
アークトゥラス・セラピューティクス・インコーポレイテッド |
オルニチントランスカルバミラーゼ欠損症の治療のための組成物及び方法
|
|
EP4117725A4
(en)
|
2020-03-09 |
2024-05-29 |
Arcturus Therapeutics, Inc. |
CORONAVIRUS VACCINE COMPOSITIONS AND METHODS
|
|
JP2023517326A
(ja)
|
2020-03-11 |
2023-04-25 |
オメガ セラピューティクス, インコーポレイテッド |
フォークヘッドボックスp3(foxp3)遺伝子発現をモジュレートするための組成物および方法
|
|
MX2022011805A
(es)
|
2020-03-24 |
2023-01-11 |
Generation Bio Co |
Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix.
|
|
CN115667531A
(zh)
|
2020-03-24 |
2023-01-31 |
世代生物公司 |
非病毒DNA载体和其用于表达戈谢(Gaucher)治疗剂的用途
|
|
EP4132478A1
(en)
|
2020-04-09 |
2023-02-15 |
Finncure Oy |
Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
|
|
US12194157B2
(en)
|
2020-04-09 |
2025-01-14 |
Finncure Oy |
Carrier for targeted delivery to a host
|
|
US12070509B2
(en)
|
2020-05-01 |
2024-08-27 |
Arcturus Therapeutics, Inc. |
Nucleic acids and methods of treatment for cystic fibrosis
|
|
US20230190954A1
(en)
|
2020-05-07 |
2023-06-22 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
EP4146342A1
(en)
|
2020-05-07 |
2023-03-15 |
Translate Bio, Inc. |
Improved compositions for cftr mrna therapy
|
|
AU2021269042A1
(en)
|
2020-05-07 |
2023-02-02 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding SARS-CoV-2 antigens
|
|
US20230226219A1
(en)
|
2020-05-14 |
2023-07-20 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
|
CA3183399A1
(en)
|
2020-05-15 |
2021-11-18 |
Translate Bio, Inc. |
Lipid nanoparticle formulations for mrna delivery
|
|
JP2023527309A
(ja)
|
2020-05-19 |
2023-06-28 |
オルナ セラピューティクス インコーポレイテッド |
環状rna組成物及び方法
|
|
IL298363A
(en)
|
2020-05-20 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and uses thereof
|
|
CN116322760A
(zh)
|
2020-05-20 |
2023-06-23 |
旗舰创业创新第六有限责任公司 |
冠状病毒抗原组合物及其用途
|
|
IL298539A
(en)
|
2020-05-29 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Trem compositions and methods relating thereto
|
|
EP4158032A2
(en)
|
2020-05-29 |
2023-04-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and methods relating thereto
|
|
CA3170740A1
(en)
|
2020-05-29 |
2021-12-02 |
Curevac Ag |
Nucleic acid based combination vaccines
|
|
US20240307556A1
(en)
|
2020-07-02 |
2024-09-19 |
Maritime Therapeutics, Inc. |
Compositions and methods for reverse gene therapy
|
|
WO2022008613A1
(en)
|
2020-07-08 |
2022-01-13 |
Janssen Sciences Ireland Unlimited Company |
Rna replicon vaccines against hbv
|
|
FI4182297T3
(fi)
|
2020-07-16 |
2025-12-05 |
Acuitas Therapeutics Inc |
Kationisia lipidejä käytettäväksi lipidinanohiukkasissa
|
|
BR112023001648A2
(pt)
|
2020-07-27 |
2023-04-04 |
Anjarium Biosciences Ag |
Moléculas de dna de fita dupla, veículo de entrega e método para preparar uma molécula de dna com extremidade em grampo
|
|
EP4172194A1
(en)
|
2020-07-31 |
2023-05-03 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|
|
US20230277457A1
(en)
*
|
2020-08-06 |
2023-09-07 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
|
IL300519A
(en)
|
2020-08-14 |
2023-04-01 |
Arcturus Therapeutics Inc |
Method for lyophilization of lipid nanoparticles
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
EP4157344A2
(en)
|
2020-08-31 |
2023-04-05 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
|
IL300947A
(en)
|
2020-09-03 |
2023-04-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and uses thereof
|
|
KR20230083323A
(ko)
|
2020-10-06 |
2023-06-09 |
트랜슬레이트 바이오 인코포레이티드 |
개선된 지질 나노입자 공정 및 제형화
|
|
US20230365995A1
(en)
|
2020-10-07 |
2023-11-16 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
|
WO2022081548A1
(en)
|
2020-10-12 |
2022-04-21 |
Translate Bio, Inc. |
Improved process of preparing ice-based lipid nanoparticles
|
|
IL301973A
(en)
|
2020-10-12 |
2023-06-01 |
Translate Bio Inc |
Improved process of preparing mrna-loaded lipid nanoparticles
|
|
MX2023004371A
(es)
|
2020-10-14 |
2023-07-26 |
George Mason Res Foundation Inc |
Lípidos ionizables, y métodos de fabricación y uso de los mismos.
|
|
US20220160633A1
(en)
|
2020-11-09 |
2022-05-26 |
Translate Bio, Inc. |
Compositions for delivery of codon-optimized mrna
|
|
KR20230113580A
(ko)
|
2020-11-25 |
2023-07-31 |
트랜슬레이트 바이오 인코포레이티드 |
안정한 액체 지질 나노입자 제형
|
|
CN117098541A
(zh)
|
2020-11-25 |
2023-11-21 |
阿卡格拉医药公司 |
用于递送核酸的脂质纳米粒及相关使用方法
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
|
WO2022135993A2
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
|
US20240175020A1
(en)
|
2020-12-23 |
2024-05-30 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
EP4267740A1
(en)
|
2020-12-28 |
2023-11-01 |
Arcturus Therapeutics, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
|
EP4277929A1
(en)
|
2021-01-14 |
2023-11-22 |
Translate Bio, Inc. |
Methods and compositions for delivering mrna coded antibodies
|
|
US20240102065A1
(en)
|
2021-01-27 |
2024-03-28 |
CureVac SE |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
|
US20250268994A1
(en)
|
2021-03-25 |
2025-08-28 |
Translate Bio, Inc. |
Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof
|
|
EP4314292A1
(en)
|
2021-03-26 |
2024-02-07 |
MiNA Therapeutics Limited |
Tmem173 sarna compositions and methods of use
|
|
JP2024511206A
(ja)
|
2021-03-26 |
2024-03-12 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
WO2022207862A2
(en)
|
2021-03-31 |
2022-10-06 |
Curevac Ag |
Syringes containing pharmaceutical compositions comprising rna
|
|
US20250073351A1
(en)
|
2021-04-19 |
2025-03-06 |
Translate Bio, Inc. |
Improved compositions for delivery of mrna
|
|
JP2024517427A
(ja)
|
2021-04-20 |
2024-04-22 |
アンジャリウム バイオサイエンシズ エージー |
アミロ-α-1,6-グルコシダーゼ、4-α-グルカノトランスフェラーゼをコードするDNA分子の組成物、その作製の方法、及びその使用の方法
|
|
US20240216535A1
(en)
|
2021-04-27 |
2024-07-04 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
CA3216585A1
(en)
|
2021-04-27 |
2022-11-03 |
Nathaniel SILVER |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
WO2022233880A1
(en)
|
2021-05-03 |
2022-11-10 |
Curevac Ag |
Improved nucleic acid sequence for cell type specific expression
|
|
US20240300914A1
(en)
*
|
2021-05-28 |
2024-09-12 |
Nanovation Therapeutics Inc. |
KC2-Type Lipids
|
|
CN117460542A
(zh)
|
2021-06-11 |
2024-01-26 |
纳米智能生物医学工程有限公司 |
包含用于将寡核苷酸递送至靶细胞内的肽-脂质缀合物的纳米颗粒以及包含其的药物组合物
|
|
JP2024527541A
(ja)
|
2021-07-01 |
2024-07-25 |
トランスレイト バイオ, インコーポレイテッド |
Mrnaの送達のための組成物
|
|
EP4362957A1
(en)
|
2021-07-01 |
2024-05-08 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
EP4367242A2
(en)
|
2021-07-07 |
2024-05-15 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
EP4377457A1
(en)
|
2021-07-26 |
2024-06-05 |
Flagship Pioneering Innovations VI, LLC |
Trem compositions and uses thereof
|
|
WO2023010135A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
US20240342206A1
(en)
|
2021-07-30 |
2024-10-17 |
CureVac SE |
mRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES
|
|
WO2023010133A2
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
KR20240042004A
(ko)
|
2021-08-03 |
2024-04-01 |
알닐람 파마슈티칼스 인코포레이티드 |
트랜스티레틴(TTR) iRNA 조성물 및 이의 사용 방법
|
|
EP4387660A1
(en)
|
2021-08-19 |
2024-06-26 |
Merck Sharp & Dohme LLC |
Thermostable lipid nanoparticle and methods of use thereof
|
|
CN113461577B
(zh)
*
|
2021-09-01 |
2021-12-14 |
中山大学附属第七医院(深圳) |
一种氨基脂质及其应用
|
|
AU2022336664A1
(en)
|
2021-09-03 |
2024-01-18 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
|
IL309505A
(en)
|
2021-09-03 |
2024-02-01 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
|
CN115745941B
(zh)
*
|
2021-09-03 |
2025-07-01 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
CN115745942B
(zh)
*
|
2021-09-03 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
CN115772089B
(zh)
*
|
2021-09-07 |
2025-06-10 |
广州谷森制药有限公司 |
阳离子脂质化合物
|
|
JP2024534428A
(ja)
|
2021-09-17 |
2024-09-20 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
環状ポリリボヌクレオチドを生成するための組成物及び方法
|
|
MX2024004618A
(es)
|
2021-10-18 |
2024-07-12 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y metodos para purificar polirribonucleotidos.
|
|
US20250027108A1
(en)
|
2021-10-29 |
2025-01-23 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
|
WO2023081526A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
|
AU2022388747A1
(en)
|
2021-11-10 |
2024-06-20 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
|
US20250352638A1
(en)
|
2021-11-24 |
2025-11-20 |
Flagship Pioneering Innovations Vi, Llc |
Coronavirus immunogen compositions and their uses
|
|
MX2024006440A
(es)
|
2021-11-24 |
2024-08-19 |
Flagship Pioneering Innovations Vi Llc |
Composiciones inmunogenicas y sus usos.
|
|
KR20240125931A
(ko)
|
2021-11-24 |
2024-08-20 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
수두-대상포진 바이러스 면역원 조성물 및 이의 용도
|
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
|
US12129223B2
(en)
|
2021-12-16 |
2024-10-29 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
TW202340460A
(zh)
|
2021-12-17 |
2023-10-16 |
美商旗艦先鋒創新有限責任公司 |
用於在變性條件下富集環狀rna之方法
|
|
KR20240117149A
(ko)
|
2021-12-22 |
2024-07-31 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
|
|
EP4452337A1
(en)
|
2021-12-23 |
2024-10-30 |
Flagship Pioneering Innovations VI, LLC |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
EP4463475A2
(en)
|
2022-01-14 |
2024-11-20 |
Anjarium Biosciences AG |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
|
EP4469091A1
(en)
|
2022-01-28 |
2024-12-04 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
|
US20250144235A1
(en)
|
2022-02-02 |
2025-05-08 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
|
KR20240161965A
(ko)
|
2022-03-14 |
2024-11-13 |
제너레이션 바이오 컴퍼니 |
이종 프라임 부스트 백신 조성물 및 사용 방법
|
|
KR20240166554A
(ko)
|
2022-03-25 |
2024-11-26 |
세일 바이오메디슨스, 인크. |
신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법
|
|
WO2023190170A1
(ja)
*
|
2022-03-28 |
2023-10-05 |
日油株式会社 |
核酸内封脂質ナノ粒子の製造方法及びこれを含む医薬品組成物の製造方法、並びに、核酸を細胞内又は標的細胞内に導入する方法
|
|
CA3255116A1
(en)
|
2022-04-01 |
2023-10-05 |
Nanovation Therapeutics Inc. |
METHOD FOR ADMINISTRATING RNA AND ASSOCIATED COMPOSITION
|
|
JP2025511756A
(ja)
|
2022-04-08 |
2025-04-16 |
フラッグシップ パイオニアリング イノベーションズ セブン,エルエルシー |
ワクチン及び関連する方法
|
|
CN119563108A
(zh)
|
2022-05-01 |
2025-03-04 |
耶达研究发展公司 |
用于减轻癌症相关恶病质的hnf4a的重表达
|
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
|
EP4522753A2
(en)
|
2022-05-13 |
2025-03-19 |
Flagship Pioneering Innovations VII, LLC |
Double stranded dna compositions and related methods
|
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
|
CA3256897A1
(en)
|
2022-05-25 |
2023-11-30 |
Akagera Medicines, Inc. |
Lipid nanoparticles for the administration of nucleic acids and their methods of use
|
|
US20250345407A1
(en)
|
2022-05-25 |
2025-11-13 |
CureVac SE |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
|
CA3258303A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Compositions of lipid nanoparticles and their uses
|
|
US20240002331A1
(en)
|
2022-06-08 |
2024-01-04 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
|
US20250179492A1
(en)
|
2022-06-22 |
2025-06-05 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
|
US12297285B2
(en)
|
2022-06-24 |
2025-05-13 |
Orna Therapeutics, Inc. |
Circular RNA encoding chimeric antigen receptors targeting BCMA
|
|
KR20250044484A
(ko)
|
2022-06-24 |
2025-03-31 |
튠 쎄라퓨틱스, 인코포레이티드 |
표적 유전자 억제를 통해 저밀도 지단백질을 감소시키기 위한 조성물, 시스템, 및 방법
|
|
CN120051297A
(zh)
|
2022-06-30 |
2025-05-27 |
因达普塔治疗公司 |
工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法
|
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
|
TW202413424A
(zh)
|
2022-08-01 |
2024-04-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
免疫調節蛋白及相關方法
|
|
EP4569112A1
(en)
|
2022-08-12 |
2025-06-18 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
|
WO2024040194A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
CN120435557A
(zh)
|
2022-08-19 |
2025-08-05 |
图恩疗法股份有限公司 |
通过靶向基因阻遏调节乙型肝炎病毒的组合物、系统和方法
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
WO2024049979A2
(en)
|
2022-08-31 |
2024-03-07 |
Senda Biosciences, Inc. |
Novel ionizable lipids and lipid nanoparticles and methods of using the same
|
|
WO2024053648A1
(ja)
|
2022-09-06 |
2024-03-14 |
国立大学法人九州大学 |
脂質ナノ粒子
|
|
EP4590821A2
(en)
|
2022-09-19 |
2025-07-30 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
|
AU2023353931A1
(en)
|
2022-09-26 |
2025-03-20 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
KR20250094676A
(ko)
*
|
2022-10-25 |
2025-06-25 |
나노베이션 테라퓨틱스 인크. |
안티-센스 올리고뉴클레오티드 전달을 위한 지질 나노입자 제형
|
|
US12186389B2
(en)
|
2022-10-28 |
2025-01-07 |
Glaxosmithkline Biologicals Sa |
Nucleic acid base vaccine against emerging SARS-CoV-2 variants
|
|
KR20250099195A
(ko)
|
2022-10-31 |
2025-07-01 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
|
|
AR131008A1
(es)
|
2022-11-08 |
2025-02-05 |
Flagship Pioneering Innovations Vi Llc |
Composiciones y métodos para producir polirribonucleótidos circulares
|
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
AU2023375897A1
(en)
|
2022-11-08 |
2025-06-12 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
CN120265279A
(zh)
|
2022-11-21 |
2025-07-04 |
翻译生物公司 |
信使rna的干粉配制品的组合物及其使用方法
|
|
JP2025541726A
(ja)
|
2022-12-01 |
2025-12-23 |
ジェネレーション バイオ カンパニー |
細胞標的化のためのステルス脂質ナノ粒子組成物
|
|
WO2024119051A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
|
|
EP4626402A1
(en)
|
2022-12-01 |
2025-10-08 |
Generation Bio Co. |
Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
|
|
KR20250129819A
(ko)
|
2022-12-01 |
2025-08-29 |
제너레이션 바이오 컴퍼니 |
핵산, 이온화 가능한 지질, 스테롤, 지질에 고정된 중합체, 및 헬퍼 지질을 포함하는 지질 나노입자 및 이의 용도
|
|
EP4630561A1
(en)
|
2022-12-09 |
2025-10-15 |
Takeda Pharmaceutical Company Limited |
Modified immunomodulators
|
|
JP2025541845A
(ja)
|
2022-12-09 |
2025-12-23 |
ソウル大学校産学協力団 |
B細胞及びT細胞内へmRNAを伝達するためのペプチド基盤結合体を含むナノ粒子及びこの用途
|
|
EP4631528A1
(en)
|
2022-12-09 |
2025-10-15 |
Nibec Co., Ltd. |
Nanoparticle comprising peptide-based conjugate for delivering oligonucleotide into target cell and pharmaceutical composition comprising same
|
|
WO2024125597A1
(en)
|
2022-12-14 |
2024-06-20 |
Providence Therapeutics Holdings Inc. |
Compositions and methods for infectious diseases
|
|
TW202430215A
(zh)
|
2022-12-14 |
2024-08-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
用於將治療劑遞送至骨之組成物和方法
|
|
AU2023398825A1
(en)
|
2022-12-15 |
2025-06-26 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
EP4633673A1
(en)
|
2022-12-15 |
2025-10-22 |
Sanofi Pasteur Inc. |
Mrna encoding influenza virus-like particle
|
|
TW202438514A
(zh)
|
2022-12-20 |
2024-10-01 |
法商賽諾菲公司 |
鼻病毒mrna疫苗
|
|
WO2024134199A1
(en)
|
2022-12-22 |
2024-06-27 |
Mina Therapeutics Limited |
Chemically modified sarna compositions and methods of use
|
|
WO2024141786A2
(en)
|
2022-12-29 |
2024-07-04 |
Popvax Private Limited |
Multitarget vaccines and therapeutics
|
|
WO2024141784A2
(en)
|
2022-12-29 |
2024-07-04 |
Popvax Private Limited |
Broadly protective betacoronavirus vaccines and compositions
|
|
US12410394B2
(en)
*
|
2023-01-06 |
2025-09-09 |
Athergen, Inc. |
Composition comprising nicotinamide mononucleotide and leucomethylene blue
|
|
TW202438673A
(zh)
|
2023-01-09 |
2024-10-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
疫苗及相關方法
|
|
WO2024151673A2
(en)
|
2023-01-09 |
2024-07-18 |
President And Fellows Of Harvard College |
Recombinant nucleic acid molecules and their use in wound healing
|
|
US20240252520A1
(en)
|
2023-01-09 |
2024-08-01 |
Beth Israel Deaconess Medical Center, Inc. |
Therapeutic agents and their use for treating chronic wounds
|
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
IL322368A
(en)
|
2023-02-03 |
2025-09-01 |
Genzyme Corp |
HSC-specific antibody-conjugated lipid nanoparticles and their uses
|
|
EP4658239A1
(en)
|
2023-02-03 |
2025-12-10 |
GlaxoSmithKline Biologicals S.A. |
Rna formulation
|
|
WO2024167885A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|
|
AU2024218499A1
(en)
*
|
2023-02-09 |
2025-08-14 |
Seqirus Inc. |
Ionizable cationic compound
|
|
IL322468A
(en)
|
2023-02-13 |
2025-09-01 |
Flagship Pioneering Innovations Vii Llc |
Ionizable lipids containing degradable crosslinkers and lipid carriers for therapeutic compositions
|
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
|
AU2024220221A1
(en)
|
2023-02-17 |
2025-08-07 |
Flagship Pioneering Innovations Vii, Llc |
Dna compositions comprising modified cytosine
|
|
EP4665405A1
(en)
|
2023-02-17 |
2025-12-24 |
Flagship Pioneering Innovations VII, LLC |
Dna compositions comprising modified uracil
|
|
DE112024001143T5
(de)
|
2023-03-08 |
2025-12-18 |
CureVac SE |
Neue lipid-nanopartikel-formeln für die abgabe von nukleinsäuren
|
|
WO2024192422A1
(en)
|
2023-03-15 |
2024-09-19 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and uses thereof
|
|
KR20250162610A
(ko)
|
2023-03-15 |
2025-11-18 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도
|
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
|
WO2024200823A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
|
|
WO2024200820A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Method of synthesis of targeted lipid nanoparticle and uses thereof
|
|
TW202449142A
(zh)
|
2023-04-07 |
2024-12-16 |
日商武田藥品工業股份有限公司 |
接合複合物
|
|
AU2024252590A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Trems for use in correction of missense mutations
|
|
AU2024255972A1
(en)
|
2023-04-12 |
2025-10-23 |
Flagship Pioneering Innovations Vi, Llc |
Modified trems, compositions, and related methods thereof
|
|
KR20250169625A
(ko)
|
2023-04-17 |
2025-12-03 |
사노피 파스퇴르 인크 |
재구성 가능한 건조 분말 제형 및 이의 사용 방법
|
|
WO2024220746A2
(en)
|
2023-04-21 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Rnai agents targeting fatty acid synthase and related methods
|
|
WO2024223728A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024223724A1
(en)
|
2023-04-27 |
2024-10-31 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
US20240376157A1
(en)
|
2023-05-08 |
2024-11-14 |
Merck Sharp & Dohme Llc |
Polynucleotides encoding norovirus vp1 antigens and uses thereof
|
|
WO2024230934A1
(en)
|
2023-05-11 |
2024-11-14 |
CureVac SE |
Therapeutic nucleic acid for the treatment of ophthalmic diseases
|
|
DE102023001946A1
(de)
|
2023-05-12 |
2024-11-14 |
Friedrich-Schiller-Universität Jena, Körperschaft des öffentlichen Rechts |
Nanopartikel für den Transport von Wirkstoffen mit anionischen Gruppen, Verfahren zu deren Herstellung und deren Verwendung
|
|
WO2024236504A1
(en)
|
2023-05-15 |
2024-11-21 |
Takeda Pharmaceutical Company Limited |
Sequences and methods for delivery of dna and rna
|
|
WO2024236361A1
(en)
|
2023-05-15 |
2024-11-21 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for delivery of nucleic acids to cells
|
|
CN116270543B
(zh)
*
|
2023-05-19 |
2023-09-26 |
清华大学 |
脂质纳米颗粒在制备通过雾吸或鼻滴给药递送核酸的药物中的用途
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
US12311033B2
(en)
|
2023-05-31 |
2025-05-27 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2024254226A1
(en)
|
2023-06-09 |
2024-12-12 |
Merck Sharp & Dohme Llc |
Nanoemulsion adjuvant compositions for human papillomavirus vaccines
|
|
WO2024258829A1
(en)
|
2023-06-12 |
2024-12-19 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025006799A1
(en)
|
2023-06-27 |
2025-01-02 |
Capstan Therapeutics, Inc. |
Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
|
|
WO2025006684A1
(en)
|
2023-06-28 |
2025-01-02 |
Flagship Pioneering Innovations Vi, Llc |
Circular polyribonucleotides encoding antifusogenic polypeptides
|
|
WO2025008774A1
(en)
|
2023-07-05 |
2025-01-09 |
Takeda Pharmaceutical Company Limited |
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
|
|
TW202515531A
(zh)
|
2023-07-07 |
2025-04-16 |
美商輝瑞股份有限公司 |
兩親性tlr7/8佐劑及其用途
|
|
WO2025011529A2
(en)
|
2023-07-07 |
2025-01-16 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna vaccines for seasonal flu and methods of uses
|
|
TW202516001A
(zh)
|
2023-07-25 |
2025-04-16 |
美商旗艦先鋒創新有限責任(Vii)公司 |
Cas內切酶及相關方法
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
US20250243274A1
(en)
*
|
2023-07-31 |
2025-07-31 |
Jibe Therapeutics, Inc. |
Compositions for Redirecting Immunoglobulins to Immune Cells
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
WO2025027116A1
(en)
|
2023-08-01 |
2025-02-06 |
Institut Curie |
Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025042786A1
(en)
|
2023-08-18 |
2025-02-27 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising circular polyribonucleotides and uses thereof
|
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
|
WO2025045142A1
(en)
|
2023-08-29 |
2025-03-06 |
Shanghai Circode Biomed Co., Ltd. |
Circular rna encoding vegf polypeptides, formulations, and methods of uses
|
|
WO2025054236A2
(en)
|
2023-09-06 |
2025-03-13 |
Flagship Pioneering Innovations Vii, Llc |
Sars-cov-2 vaccine compositions and related methods
|
|
WO2025052180A2
(en)
|
2023-09-07 |
2025-03-13 |
Axelyf ehf. |
Lipids and lipid nanoparticles
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
TW202525266A
(zh)
|
2023-09-18 |
2025-07-01 |
美商旗艦先鋒創新有限責任(Vii)公司 |
可電離類脂質組成物及其治療用途
|
|
WO2025063214A1
(ja)
*
|
2023-09-22 |
2025-03-27 |
国立大学法人東北大学 |
核酸を内封したリガンド修飾脂質ナノ粒子の製造方法
|
|
WO2025072331A1
(en)
|
2023-09-26 |
2025-04-03 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025096807A2
(en)
|
2023-10-31 |
2025-05-08 |
Flagship Pioneering Innovations Vii, Llc |
Novel therapeutic dna forms
|
|
WO2025101501A1
(en)
|
2023-11-07 |
2025-05-15 |
Orna Therapeutics, Inc. |
Circular rna compositions
|
|
TW202535835A
(zh)
|
2023-11-14 |
2025-09-16 |
美商旗艦先鋒創新有限責任(Vii)公司 |
可電離類脂質組成物及其治療用途
|
|
US20250161347A1
(en)
|
2023-11-22 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
WO2025117877A2
(en)
|
2023-12-01 |
2025-06-05 |
Flagship Pioneering Innovations Vii, Llc |
Cas nucleases and related methods
|
|
WO2025129128A1
(en)
|
2023-12-15 |
2025-06-19 |
Vivasor, Inc. |
Compositions and methods for non-viral delivery of therapeutic compounds
|
|
WO2025133115A1
(en)
|
2023-12-21 |
2025-06-26 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising il-35
|
|
WO2025132839A1
(en)
|
2023-12-21 |
2025-06-26 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
|
US20250375499A1
(en)
|
2024-01-26 |
2025-12-11 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025174825A2
(en)
|
2024-02-12 |
2025-08-21 |
Aera Therapeutics, Inc. |
Delivery compositions
|
|
WO2025180874A1
(en)
*
|
2024-02-27 |
2025-09-04 |
Basf Se |
Substituted 1,3-dioxolane sulfates and their use
|
|
WO2025190300A1
(zh)
*
|
2024-03-13 |
2025-09-18 |
仁景(苏州)生物科技有限公司 |
脂质纳米颗粒及脂质纳米颗粒组合物
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025196065A1
(en)
|
2024-03-20 |
2025-09-25 |
Sanofi |
Novel homocysteine based lipids and their use for delivery of nucleic acids
|
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|
|
WO2025217275A2
(en)
|
2024-04-10 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Immune cell targeted compositions and related methods
|
|
CN118388360B
(zh)
|
2024-04-17 |
2025-04-04 |
北京悦康科创医药科技股份有限公司 |
含有苯环结构的长效脾靶向阳离子脂质化合物、包含其的组合物及用途
|
|
WO2025240680A1
(en)
|
2024-05-16 |
2025-11-20 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor inhibitory proteins and related methods
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025245111A1
(en)
|
2024-05-22 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Immunoreceptor targeting proteins and related methods
|
|
WO2025250751A1
(en)
|
2024-05-31 |
2025-12-04 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
|
WO2025252759A1
(en)
|
2024-06-03 |
2025-12-11 |
Bio-Sourcing |
Transient expression by lipid nanoparticle formulations
|
|
WO2025259931A1
(en)
|
2024-06-14 |
2025-12-18 |
Orbital Therapeutics, Inc. |
Compositions and methods for rna circularization
|